|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
50,296,000 |
Market
Cap: |
205.71(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.9 - $40.3 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in the development of therapies for patients living with inflammatory diseases and autoimmune disorders. Co.'s product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis and Crohn's disease, among other potential indications. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for ulcerative colitis. Co.'s oral, selective and peripherally restricted NLRP3 inhibitor, VTX2735, has been designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
9,019 |
90,800 |
3,592,266 |
6,036,052 |
Total Sell Value |
$48,733 |
$221,937 |
$56,317,001 |
$133,915,096 |
Total People Sold |
4 |
4 |
7 |
8 |
Total Sell Transactions |
4 |
7 |
60 |
103 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-03-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(591,276) |
11,824,143 |
|
- |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2023-03-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(559,367) |
12,415,419 |
|
- |
|
Subramaniam Somu |
Director |
|
2023-03-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(559,367) |
12,415,419 |
|
- |
|
White William Richard |
Director |
|
2023-01-23 |
4 |
AS |
$34.33 |
$1,170,592 |
D/D |
(33,353) |
0 |
|
-3% |
|
White William Richard |
Director |
|
2023-01-23 |
4 |
OE |
$6.03 |
$201,119 |
D/D |
33,353 |
33,353 |
|
- |
|
Mohan Raju |
Chief Executive Officer |
|
2022-12-22 |
4 |
S |
$31.61 |
$1,749,640 |
D/D |
(55,354) |
1,603,126 |
|
-22% |
|
Krueger Christopher W |
Chief Business Officer |
|
2022-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,480 |
286,324 |
|
- |
|
Nuss John |
Chief Scientific Officer |
|
2022-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,931 |
258,627 |
|
- |
|
Mohan Raju |
Chief Executive Officer |
|
2022-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
116,669 |
1,658,480 |
|
- |
|
Subramaniam Somu |
Director |
|
2022-12-16 |
4 |
S |
$32.94 |
$4,836,797 |
I/I |
(146,825) |
12,974,786 |
|
-15% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2022-12-16 |
4 |
S |
$32.94 |
$4,836,797 |
I/I |
(146,825) |
12,974,786 |
|
-15% |
|
Subramaniam Somu |
Director |
|
2022-12-15 |
4 |
S |
$33.61 |
$5,148,227 |
I/I |
(153,175) |
13,121,611 |
|
-9% |
|
Nsv Partners Iii Gp Llc |
10% Owner |
|
2022-12-15 |
4 |
S |
$33.61 |
$5,148,227 |
I/I |
(153,175) |
13,121,611 |
|
-9% |
|
Sandborn William J. |
See Remarks |
|
2022-12-14 |
4 |
S |
$33.87 |
$708,632 |
I/I |
(20,922) |
34,877 |
|
-8% |
|
Sandborn William J. |
See Remarks |
|
2022-12-14 |
4 |
OE |
$0.20 |
$4,184 |
I/I |
20,922 |
55,799 |
|
- |
|
Sandborn William J. |
See Remarks |
|
2022-12-14 |
4 |
S |
$33.87 |
$737,085 |
D/D |
(21,760) |
48,389 |
|
-8% |
|
Sandborn William J. |
See Remarks |
|
2022-12-14 |
4 |
OE |
$0.20 |
$17,217 |
D/D |
21,760 |
70,149 |
|
- |
|
Nuss John |
Chief Scientific Officer |
|
2022-12-13 |
4 |
S |
$34.32 |
$1,201,078 |
D/D |
(35,000) |
223,696 |
|
-10% |
|
Subramaniam Somu |
Director |
|
2022-12-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,341,262) |
13,274,786 |
|
- |
|
Krueger Christopher W |
Chief Business Officer |
|
2022-12-13 |
4 |
S |
$34.46 |
$1,033,668 |
D/D |
(30,000) |
272,692 |
|
-10% |
|
Nsv Investments I, L.p. |
10% Owner |
|
2022-12-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,341,262) |
13,274,786 |
|
- |
|
Nuss John |
Chief Scientific Officer |
|
2022-12-05 |
4 |
S |
$28.16 |
$1,411,311 |
D/D |
(50,000) |
258,696 |
|
-20% |
|
Mohan Raju |
Chief Executive Officer |
|
2022-12-05 |
4 |
S |
$28.33 |
$654,130 |
D/D |
(23,003) |
1,541,811 |
|
-20% |
|
Krueger Christopher W |
Chief Business Officer |
|
2022-12-02 |
4 |
S |
$29.01 |
$1,450,730 |
D/D |
(50,000) |
302,692 |
|
-3% |
|
Mohan Raju |
Chief Executive Officer |
|
2022-12-02 |
4 |
S |
$29.01 |
$8,036,957 |
D/D |
(276,997) |
1,564,814 |
|
-3% |
|
178 Records found
|
|
Page 6 of 8 |
|
|